Clinical Trial Update: A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial studying Anti-CD70 UCAR-T for relapsed or refractory solid tumors, with not yet recruiting status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Head and Neck Squamous Cell Carcinoma
• Nasopharyngeal Carcinoma
• Ovarian Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Anti-CD70 UCAR-T

Snippet

Sponsor: Zhejiang University | Conditions: Metastatic Tumor, Advanced Solid Tumor | Phase 1 | Status: NOT_YET_RECRUITING